Evoke Pharma INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
EVOK
Evoke Pharma INCEvoke Pharma reported strong Q3 2025 sales growth for Gimoti and announced a definitive merger agreement to be acquired by QOL Medical for $11.00 per share in cash.
EVOK
Evoke Pharma INCEvoke Pharma reported significant revenue growth for its Gimoti nasal spray in the second quarter of 2025, yet continues to face substantial doubt regarding its ability to continue as a going concern.
EVOK
Evoke Pharma INC10-Q: Evoke Pharma Reports Increased Net Product Sales in Q1 2025, but Going Concern Uncertainty Remains
Evoke Pharma's Q1 2025 shows a significant increase in net product sales of Gimoti, but the company expresses substantial doubt about its ability to continue as a going concern due to potential termination of the Eversana agreement and the need for additional funding.
EVOK
Evoke Pharma INCEvoke Pharma's Q3 2024 results show a significant increase in net product sales, but the company expresses substantial doubt about its ability to continue as a going concern.
EVOK
Evoke Pharma INCEvoke Pharma saw a significant increase in net product sales and made progress towards Nasdaq listing compliance in the second quarter of 2024, while still facing going concern challenges.
EVOK
Evoke Pharma INC10-Q: Evoke Pharma Reports Increased Sales but Continues to Face Going Concern Challenges in Q1 2024
Evoke Pharma's Q1 2024 results show a significant increase in net product sales of Gimoti, but the company still faces substantial doubt about its ability to continue as a going concern.